SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US OTC > Biotechs >

Innovus Pharmaceuticals, Inc. (INNV)

INNV RSS Feed
Add INNV Price Alert      Hide Sticky   Hide Intro
Moderator: BooDog, kkpennies, cash4, Peter Lynch, NewTrader2017, pharmacyman
Search This Board: 
Last Post: 5/26/2017 10:43:35 AM - Followers: 125 - Board type: Free - Posts Today: 26

  


http://www.innovuspharma.com

https://twitter.com/innovuspharma


http://shop.innovuspharma.com/
* shareholders, please consider purchasing product(s)


***ALERT***

Awaiting Official Announcement of FDA Approval for FlutiCare



 
FlutiCare Approval could bring a BILLION DOLLARS in sales annually

REDONDO BEACH, CA--(Marketwired - Jul 12, 2016) - SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, discusses the potential impact of the anticipated FDA ruling on Innovus Pharmaceuticals' (OTCQB: INNV) ANDA filing for FlutiCare™, the company's over-the-counter treatment for allergic rhinitis.

FlutiCare™ is designed to treat non-allergic rhinitis -- better known as "hay fever" or "stuffy nose" -- which affects roughly 50 million Americans each year. While 70% of these individuals use over-the-counter products, more than half are not satisfied with the treatment option, according to an Asthma and Allergy Foundation of America survey, which suggests there's an opportunity for a prescription-strength OTC treatment option to capture market share from category leaders.

As the #1 prescription nasal steroid with over 177 million units sold since 2007, Innovus believes that the over-the-counter version of FlutiCare™ could be worth up to $1 billion per year by addressing a much wider over-the-counter market. The FDA decision is expected in the next several weeks.
 

 


The CEO has already signed an agreement for the manufacturing of FlutiCare

 
Innovus Pharma Achieves Major Milestone With Securing a Manufacturing Agreement for FlutiCare in Anticipation of the FDA Decision

SAN DIEGO, CA--(Marketwired - May 31, 2016) - Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB: INNV), an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men and women's health and respiratory diseases, today announced that it signed a manufacturing agreement for the supply of its FlutiCare™ 60 and 120 spray/bottles.  Innovus signed the agreement in anticipation of the FDA's decision, expected between July-September of this year, on the ANDA application for the drug.
 



 

Prior to joining Innovus Pharma,

Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. 
where he helped move the company's stock price from
19 Cents to $6.00 !!!
(Uplisted from OTC to NASDAQ)
 

 
 

Company Profile:

Headquartered in San Diego, Innovus Pharma is an emerging leader in OTC and consumer products for men's and women's health and vitality. The Company generates revenues from its lead products (a) BTH® Testosterone Booster, (b) BTH® Human Growth Agent, (c) Zestra® for female arousal and (d) EjectDelay® for premature ejaculation and has an additional five marketed products in this space, including (e) Sensum® for the indication of reduced penile sensitivity, (for sales outside the U.S. only), (f) Zestra Glide®, (g)Vesele® for promoting sexual and cognitive health, (i) Androferti® (in the US and Canada) to support overall male reproductive health and sperm quality, (j) BTH Vision Formula, (k) BTH Blood Sugar, among others and eventually FlutiCare™ OTC for Allergic Rhinitis, if its ANDA is approved by the U.S. FDA.


Business Summary:

Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a non-medicated patented consumer care product to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine-based topical gel for treating premature ejaculation; Sensum+, a non-medicated consumer care cream that enhances penile sensitivity; Zestra Glide, a high viscosity and low osmolality water-based lubricant; Vesele, a proprietary oral dietary supplement to enhance nitric oxide beneficial clinical effects on sexual functions and brain health; and Androferti to support overall male reproductive health and sperm quality. The company?s pipeline products includes FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was incorporated in 2011 and is based in San Diego, California.


Bassam Damaj, Ph.D.
President and Chief Executive Officer:


Dr. Bassam Damaj was appointed to serve as our President and Chief Executive Officer in January 2013. Prior to joining Innovus Pharma, Dr. Damaj served as President and Chief Executive Officer of Apricus Biosciences, Inc. (NASDAQ: APRI), a specialty pharmaceutical company, from December 2009 until November 2012. At Apricus Bio, Dr. Damaj was responsible for the approval of its lead drug Vitaros, a treatment for erectile dysfunction. Dr. Damaj also signed multimillion dollar partnerships between Apricus Bio and leading pharmaceutical companies such as Abbott, Novartis-Sandoz and Takeda. Before Apricus Bio, Dr. Damaj was a co-founder of Bio-Quant, Inc. and served as the Chief Executive Officer and Chief Scientific Officer and a Director of Bio-Quant's board of directors from its inception in June 2000 until its acquisition by Apricus Biosciences in December 2009. In addition, Dr. Damaj was the founder, Chairman, President and Chief Executive Officer of R&D Healthcare, and the co-founder of Celltek Biotechnologies. He also served as a Director of the Board of Directors at CreAgri, Inc. and was a Member of the Scientific Advisory Board of MicroIslet, Inc. He is the author of the Immunological Reagents and Solutions reference book, the inventor of many patents and author of numerous peer reviewed scientific publications. Dr. Damaj won a US Congressional award for the Anthrax Multiplex Diagnostic Test in 2003. Dr. Damaj holds a Ph.D. degree in Immunology/Microbiology from Laval University and completed a postdoctoral fellowship in molecular oncology from McGill University.
 



Who are the major players at Innovus Pharma?




 

Share Structure:


Shares Outstanding:     150.5 Million (as of 4/28/17)   Dr. Damaj owns $23.7M shares.  Novalere owns 25.6M.  One person and One Entity own ~ 32.8% of the outstanding shares. 

Profitability expected exiting Q4 2017 !
- 2017 Projected Revenue of $15M (NOT counting FlutiCare), which would be approximately 3x GREATER than 2016. 

 
 
Products:
https://www.ooyess.bargains/

http://www.innovuspharma.com/products_OTC_mh.php#top



Company Videos:

Innovus Pharma CEO Provides Shareholder Update and Conference Call
http://finance.yahoo.com/news/innovus-pharma-ceo-provides-shareholder-101000536.html

https://www.youtube.com/watch?v=FT9MP0OiMqU

https://www.youtube.com/watch?v=w-FKfRaSj0Y

https://www.youtube.com/watch?v=f7YnqjVLVg0

https://www.youtube.com/watch?v=mqM_dY5Wz3s




Corporate Presentation November 2016 (8-K  11/1/2016)
http://client.irwebkit.com/innovuspharma/filings?qm_page=38298


Upcoming PDUFA and ANDA Approval Dates Could Catalyze Innovus Pharma (INNV) and Lipocine (LPCN)
http://finance.yahoo.com/news/upcoming-pdufa-anda-approval-dates-140000806.html


Innovus Pharma (INNV): Targeting $3+ Billion Markets With 13 Commercial Products
http://finance.yahoo.com/news/innovus-pharma-innv-targeting-3-150320014.html




Major 2016 Accomplishments:



 

 


Where can INNV products be seen?





 


Existing Product Lines @ Innovus Pharma:

http://shop.innovuspharma.com/


Newest Product:

http://www.prostagorx.com/

WHAT IS PROSTAGORX™?

PROSTAGORX™ is a clinical strength, multi response prostate supplement, scientifically formulated to effectively maintain good prostate health and help in prevent prostate issues in the future. ProstaGorx™ was developed by top medical doctors and produced in a top-quality, cGMP certified and FDA registered laboratory environment under the most rigorously professional conditions. 

The positive benefits provided by the individual and combination ingredients in ProstaGorx™ have been published in leading medical journals.


_________________________________________________________________________________________________________________________________________________________________________
















Are you looking to boost your brain health?r
               http://www.recalmax.com/


http://www.urivarx.com/





http://www.myandroferti.com/

https://www.myvesele.com/

https://www.ooyess.bargains/

** Help to get the word out and be a PRODUCT AMBASSADOR for YOUR company

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
INNV
Current Price
Volume:
Bid Ask Day's Range
INNV News: Current Report Filing (8-k) 05/22/2017 06:05:29 AM
INNV News: Current Report Filing (8-k) 05/16/2017 06:12:08 AM
INNV News: Quarterly Report (10-q) 05/15/2017 06:11:33 AM
INNV News: Current Report Filing (8-k) 05/12/2017 04:08:50 PM
INNV News: Current Report Filing (8-k) 05/09/2017 06:11:15 AM
PostSubject
#9455  Sticky Note Heavily shorted almost 3 Mil shares looking to cover. cash4 05/23/17 10:41:56 AM
#9167  Sticky Note 10-Q Our Products BooDog 05/15/17 07:56:30 AM
#6430  Sticky Note Innovus Pharma Announces Receipt of Notification to Commercialize kkpennies 03/08/17 04:20:02 PM
#9647   yes yes come little lambs TrueTrades 05/26/17 10:43:35 AM
#9646   This is NOT meant to PUMP...but 2 separate Honeycomb777 05/26/17 10:39:15 AM
#9645   Sure... prob another bunch of bagholders at .13+ TRUMPFORPRES 05/26/17 10:32:47 AM
#9644   Great profit, , more coming... all the bashers tnc26 05/26/17 10:24:12 AM
#9643   To the Day Traders...THINK, as here are 4 Honeycomb777 05/26/17 10:10:44 AM
#9642   So you are BI??? LMAO. Batermere 05/26/17 10:04:25 AM
#9641   this is a swing trade. i make money TRUMPFORPRES 05/26/17 10:02:42 AM
#9640   You're going to get torched, Trump. mulally 05/26/17 10:00:32 AM
#9639   On fire. Nothing can stop this now. mulally 05/26/17 10:00:07 AM
#9638   Yes.. keep the low bids coming. I will TRUMPFORPRES 05/26/17 09:57:13 AM
#9637   Only time i lose money was when i TRUMPFORPRES 05/26/17 09:52:17 AM
#9636   If the bashers that have turned LONG would Honeycomb777 05/26/17 09:52:06 AM
#9635   Make sure you pay your rent in advance, cash4 05/26/17 09:51:34 AM
#9634   Seethru gets paid by DAMAGE for publishing pumping TRUMPFORPRES 05/26/17 09:49:54 AM
#9633   YES ADDING MORE TODAY! TRUMPFORPRES 05/26/17 09:47:42 AM
#9632   Could run all the way into the Q2 Honeycomb777 05/26/17 09:47:16 AM
#9631   Are you still short here ? cash4 05/26/17 09:45:03 AM
#9630   We're off folks. Finally. mulally 05/26/17 09:42:43 AM
#9629   Welcome Newbies !! Now that most of you Honeycomb777 05/26/17 09:40:39 AM
#9628   Bid already above .12 this morning. cash4 05/26/17 09:18:53 AM
#9627   Thanks, nice report, wish I could buy more nFUSZmywallet 05/26/17 08:49:41 AM
#9626   Found it, nice .65 price target nFUSZmywallet 05/26/17 08:45:52 AM
#9625   It's posted on Yahoo Finance. mulally 05/26/17 08:45:48 AM
#9624   Can't seem to find a link nFUSZmywallet 05/26/17 08:44:46 AM
#9623   Should be a nice / steady day of Honeycomb777 05/26/17 08:25:57 AM
#9622   Seethru equity PR out mulally 05/26/17 07:41:38 AM
#9621   Nice large Vesele ad - 9 days ago !! Honeycomb777 05/25/17 11:34:43 PM
#9620   You and I are like minds my friend. mulally 05/25/17 10:32:28 PM
#9619   I agree, there are many OTC companies overvalued nFUSZmywallet 05/25/17 10:27:12 PM
#9618   Way undervalued. It should be trading mulally 05/25/17 10:12:08 PM
#9617   No, true trades, I haven't looked at the nFUSZmywallet 05/25/17 10:07:34 PM
#9616   Talking to me Nfusz? mulally 05/25/17 10:03:05 PM
#9615   I'm guessing from your name that you're a nFUSZmywallet 05/25/17 09:54:52 PM
#9614   I wouldn't be surprised I think he was nFUSZmywallet 05/25/17 09:51:17 PM
#9612   Give it a rest "basher trump" Somebody is nervous. mulally 05/25/17 09:42:06 PM
#9609   It's red anything below 0.30!!!!!!!!!!!!!!! TRUMPFORPRES 05/25/17 04:36:40 PM
#9608   i have 100% confident this is set up TRUMPFORPRES 05/25/17 04:36:02 PM
#9607   GREEN ... mike007 05/25/17 04:23:30 PM
#9606   Trump all you're doing is making people like mulally 05/25/17 03:45:43 PM
#9605   QUIT SHOUTING!!!! We hear just fine. Take your Batermere 05/25/17 03:39:22 PM
#9604   WE SHOULD ONE QUESTIOn. CAN YOU PROVIDE THE TRUMPFORPRES 05/25/17 03:39:16 PM
#9603   EVEN TOCA (Recent IPO) has a lower SG&A TRUMPFORPRES 05/25/17 03:27:49 PM
#9601   Actually I had you as the hottest candidate jtaylor68 05/25/17 03:19:57 PM
#9591   KEEP PUMPING PUMPERS! I bet company is diluting TRUMPFORPRES 05/25/17 02:48:17 PM
#9589   TRUMP - look you have speech Diarrhea..... healthywelth 05/25/17 02:19:29 PM
#9588   TrueTrump GTTTR15 05/25/17 02:13:39 PM
#9585   got 220k and adding all day! TrueTrades 05/25/17 01:49:36 PM
#9584   12s printing!!!!! TrueTrades 05/25/17 01:48:49 PM
#9583   panic buying going on TrueTrades 05/25/17 01:48:21 PM
#9582   clear out these 11s and its thin to 20 TrueTrades 05/25/17 01:47:42 PM
PostSubject